Table 2. Unity-aligned seroprevalence data points of the Serotracker dataset [33] that use assays at high risk of seroreversion, defined as lateral flow assays or quantitative-indirect assays for SARS-CoV-2 nucleocapsid antibodies, January 2020–December 2021 (n = 1,592).
| Period of serological sampling | SeroTracker data points at high seroreversion risk (total data points) | Percentage of assays at high seroreversion risk (%) |
|---|---|---|
| 1 Jan–30 Jun 2020 | 135 (506) | 26.9 |
| 1 Jul–31 Dec 2020 | 140 (596) | 23.4 |
| 1 Jan–30 Jun 2021 | 58 (330) | 17.5 |
| 1 Jul–31 Dec 2021 | 10 (160) | 6.3 |
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.